Clinical trial
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory…
NCT00216697 · Janssen Pharmaceutical K.K., Industry · Completed
Key facts
| NCT number | NCT00216697 |
|---|---|
| Title | An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy |
| Official title | An Extension or Re-Treatment Study of Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 13 |
| Start date | Mar 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: